After facing broader market tumult and divestments, precision medicine company Tempus’ post-IPO success could indicate medtech sector stability to come. Valuation multiples are beginning to stabilize, and VC deals are back on the rise after the post-pandemic lull. Analysts expect strong cash flow and profit growth for the sector in 2025 as market conditions improve. PitchBook’s Q3 2024 Medtech Public Comp Sheet and Valuation Guide tracks stock performances, valuations, revenue growth, and EBITDA margins for key publicly traded companies.
Read the full article: PitchBook Q3 2024 Medtech Public Comp Sheet and Valuation Guide //
Source: https://pitchbook.com/news/reports/q3-2024-medtech-public-comp-sheet-and-valuation-guide